TrialBMJ open diabetes research & care2020

Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week results from the DURATION-NEO-1 study.

Carol H Wysham et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.